Journal ArticleDOI
Children's Oncology Group's 2013 blueprint for research: Neuroblastoma
Julie R. Park,Rochelle Bagatell,Wendy B. London,John M. Maris,Susan L. Cohn,Katherine M. Mattay,Michael D. Hogarty +6 more
Reads0
Chats0
TLDR
The incorporation of targeted radionuclide therapy prior to myeloablative chemotherapy into high‐risk treatment and druggable target(s) including mTOR inhibition and GD2‐directed therapy in combination with chemotherapy for patients with recurrent neuroblastoma, and ALK inhibition for those with ALK‐aberrant tumors are studied.Abstract:
Estimated 5-year survival rates for patients with non-high-risk and high-risk neuroblastoma are 90% and 50%, respectively. Recent clinical trials have shown excellent outcomes with reduced therapy for non-high-risk disease. For patients with high-risk neuroblastoma treated with chemoradiotherapy, surgery, and stem cell transplantation, the addition of anti-disialoganglioside (GD2) immunotherapy plus cytokines improves survival. Upcoming trials will study the incorporation of targeted radionuclide therapy prior to myeloablative chemotherapy into high-risk treatment. Phase 2 trials will investigate druggable target(s) including mTOR inhibition and GD2-directed therapy in combination with chemotherapy for patients with recurrent neuroblastoma, and ALK inhibition for those with ALK-aberrant tumors.read more
Citations
More filters
Journal ArticleDOI
Neuroblastoma
TL;DR: Neuroblastoma is a type of cancer that most often affects children and can spread to other parts of the body such as the bones, liver, or skin.
Journal ArticleDOI
Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations
Thomas F. Eleveld,Derek A. Oldridge,Virginie Bernard,Jan Koster,Leo Colmet Daage,Sharon J. Diskin,Linda Schild,Nadia Bessoltane Bentahar,Angela Bellini,Mathieu Chicard,Eve Lapouble,Valérie Combaret,Patricia Legoix-Né,Jean Michon,Trevor J. Pugh,Lori S. Hart,JulieAnn Rader,Edward F. Attiyeh,Jun S. Wei,Shile Zhang,Arlene Naranjo,Julie M. Gastier-Foster,Michael D. Hogarty,Shahab Asgharzadeh,Malcolm A. Smith,Jaime M. Guidry Auvil,Thomas B.K. Watkins,Danny A. Zwijnenburg,Marli E. Ebus,Peter van Sluis,Anne Hakkert,Esther M. van Wezel,C. Ellen van der Schoot,Ellen M. Westerhout,Johannes H. Schulte,Godelieve A.M. Tytgat,M. Emmy M. Dolman,Isabelle Janoueix-Lerosey,Daniela S Gerhard,Huib N. Caron,Olivier Delattre,Javed Khan,Rogier Versteeg,Gudrun Schleiermacher,Jan J. Molenaar,John M. Maris +45 more
TL;DR: It is shown that RAS-MAPK pathway mutations may function as a biomarker for new therapeutic approaches to refractory disease and provide a rationale for genetic characterization of relapse neuroblastomas.
Journal ArticleDOI
Neuroblastoma: Paradigm for Precision Medicine
Meredith S. Irwin,Julie R. Park +1 more
TL;DR: Current clinical trials have continued to reduce therapy for patients with non-high-risk NB, including the most favorable subsets who are often followed with observation approaches, and high-risk patients are treated aggressively with chemotherapy, radiation, surgery, and myeloablative and immunotherapies.
Journal ArticleDOI
Neuroblastoma: Molecular Pathogenesis and Therapy
TL;DR: Systematic classification of patients coupled with therapeutic advances point to a future of improved clinical outcomes for this biologically distinct and highly aggressive pediatric malignancy.
Journal ArticleDOI
Neuroblastoma: Clinical and Biological Approach to Risk Stratification and Treatment
TL;DR: The goal has been to decrease therapy for low-risk patients to avoid long-term complications while augmenting and targeting therapies for high- risk patients to improve overall survival.
References
More filters
Journal ArticleDOI
Chronic Health Conditions in Adult Survivors of Childhood Cancer
Kevin C. Oeffinger,Ann C. Mertens,Charles A. Sklar,Toana Kawashima,Melissa M. Hudson,Anna T. Meadows,Debra L. Friedman,Neyssa Marina,Wendy L. Hobbie,Nina S. Kadan-Lottick,Cindy L. Schwartz,Wendy M. Leisenring,Leslie L. Robison +12 more
TL;DR: Survivors of childhood cancer have a high rate of illness owing to chronic health conditions, including severe, disabling, or life-threatening conditions or death due to a chronic condition.
Journal ArticleDOI
Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage
Garrett M. Brodeur,Robert C. Seeger,Robert C. Seeger,Manfred Schwab,Harold E. Varmus,J M Bishop +5 more
TL;DR: N-myc amplification is highly correlated with advanced stages of disease (P less than 0.001) and with the ability to grow in vitro as an established cell line, both of which are associated with a poor prognosis.
Journal ArticleDOI
Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.
Garrett M. Brodeur,J Pritchard,Frank Berthold,N L Carlsen,Victoria Castel,R P Castelberry,B. De Bernardi,Audrey E. Evans,Favrot M,F Hedborg +9 more
TL;DR: The International Neuroblastoma Staging System (INSS) as mentioned in this paper was proposed to establish an internationally accepted staging system for neuroblastoma, as well as consistent criteria for confirming the diagnosis and determining response to therapy.
Journal ArticleDOI
Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas.
Robert C. Seeger,Garrett M. Brodeur,Harland N. Sather,Andree Dalton,Stuart E. Siegel,Kwan Y. Wong,Denman Hammond +6 more
TL;DR: The results suggest that genomic amplification of N-myc may have a key role in determining the aggressiveness of neuroblastomas.
Journal ArticleDOI
Recent advances in neuroblastoma.
TL;DR: The author discusses recent advances in the understanding of neuroblastoma, an embryonal cancer of the autonomic nervous system, which has one of the highest rates of spontaneous and complete regression.
Related Papers (5)
Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
Alice L. Yu,Andrew L. Gilman,M. Fevzi Ozkaynak,Wendy B. London,Susan G. Kreissman,Helen X. Chen,Malcolm A. Smith,Barry D. Anderson,Judith G. Villablanca,Katherine K. Matthay,H. Shimada,Stephan A. Grupp,Robert C. Seeger,C. Patrick Reynolds,Allen Buxton,Ralph A. Reisfeld,Steven D. Gillies,Susan L. Cohn,John M. Maris,Paul M. Sondel +19 more
The genetic landscape of high-risk neuroblastoma
Trevor J. Pugh,Olena Morozova,Edward F. Attiyeh,Edward F. Attiyeh,Shahab Asgharzadeh,Shahab Asgharzadeh,Jun S. Wei,Daniel Auclair,Scott L. Carter,Kristian Cibulskis,Megan Hanna,Megan Hanna,Adam Kiezun,Jaegil Kim,Michael S. Lawrence,Lee Lichenstein,Aaron McKenna,Chandra Sekhar Pedamallu,Chandra Sekhar Pedamallu,Alex H. Ramos,Alex H. Ramos,Erica Shefler,Andrey Sivachenko,Carrie Sougnez,Chip Stewart,Adrian Ally,Inanc Birol,Readman Chiu,Richard Corbett,Martin Hirst,Shaun D. Jackman,Baljit Kamoh,Alireza Hadj Khodabakshi,Martin Krzywinski,Allan Lo,Richard A. Moore,Karen Mungall,Jenny Q. Qian,Angela Tam,Nina Thiessen,Yongjun Zhao,Kristina A. Cole,Kristina A. Cole,Maura Diamond,Maura Diamond,Sharon J. Diskin,Sharon J. Diskin,Yael P. Mosse,Yael P. Mosse,Andrew Wood,Andrew Wood,Lingyun Ji,Lingyun Ji,Richard Sposto,Richard Sposto,Thomas C. Badgett,Wendy B. London,Yvonne Moyer,Yvonne Moyer,Julie M. Gastier-Foster,Julie M. Gastier-Foster,Malcolm A. Smith,Jaime M. Guidry Auvil,Daniela S. Gerhard,Michael D. Hogarty,Michael D. Hogarty,Steven J.M. Jones,Eric S. Lander,Stacey Gabriel,Gad Getz,Robert C. Seeger,Robert C. Seeger,Javed Khan,Marco A. Marra,Matthew Meyerson,Matthew Meyerson,John M. Maris +76 more